Singapore, July 16 -- Insilico Medicine, a Hong Kong-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has announced a multi-target strategic alliance with Taiwan's Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing.

The proposed alliance will be governed by definitive agreements to be discussed and executed by Insilico and Bora and is designed to combine Insilico's proprietary Pharma.AI platform, spanning target discovery, generative chemistry, and molecule optimization, with Bora's global development, manufacturing, quality, and commercialisation capabilities.

By linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution, Insilico a...